Sotradecol

(Sodium tetradecyl sulfate)

Phase 1Small molecule

HHelsinn Therapeutics (U.S.), Inc

Sotradecol is one of 4 small molecule programs targeting Varicose veins. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Varicose VeinsActive, not recruiting

Varicose VeinsPhase 1

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Varicose Veins

#DrugCompanyPhaseTrials

Heparin Sodium

BBaxter Healthcare Corporation

Approved

—2

Calcium Dobesilate

GGuizhou Bailing Group Pharmaceutical Co Ltd

Approved

1 3

Sotradecol

HHelsinn Therapeutics (U.S.), Inc

Phase 1

1 4

Polidocanol Foam Sclerotherapy

HHospital Universitario Pedro Ernesto

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bleeding1 trial

Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding

Unknown status·KKaohsiung Veterans General Hospital.·Phase 3·NCT06106971·68 enrolled

Treatment1 trial

Treatment of Epidermoid Cysts

Unknown status·GGoldman, Butterwick, Fitzpatrick and Groff·Phase 2·NCT05597995·10 enrolled

Varicose veins1 trial

is Ultrasound-guided Foam Sclerotherapy a Cost-effective Alternate for Treatment of Varicose Veins?

Unknown status·—·Phase 1·NCT04655417·70 enrolled

Unspecified1 trial

Perforator Vein Injection for Symptomatic Venous Disease

Terminated·EEllen Dillavou·N/A·NCT03363633·12 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

SOTRADECOL

NDA NDA005970

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Sodium tetradecyl sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium tetradecyl sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium tetradecyl sulfate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA005970). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Helsinn Therapeutics (U.S.), Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHelsinn Therapeutics (U.S.), Inc

Sotradecol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bleeding1 trial

Treatment1 trial

Varicose veins1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News